ReviewMedicina (Kaunas, Lithuania)2025
Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD.
Review in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-HDL-to-HDL-cholesterol ratio and metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy.Acta diabetologica · 2026 · on this mapTrial
- A Simple Clinical Prediction Model for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Obesity.Indian journal of pediatrics · 2026Article
- A Bedside Score for MASLD in Adolescents with Obesity.Indian journal of pediatrics · 2026Article
- An Explainable AI Tool (FibroX) for Detecting Advanced Liver Fibrosis in Adults With Type 2 Diabetes: Protocol for a Pilot Crossover Trial.JMIR research protocols · 2026Article
- Microbial Consortia-Immunoglobulin G Glycosylation Combination Scores Identify Severe Hepatic Steatosis and Significant Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Clinical and translational gastroenterology · 2026Article
- Blood markersWorld journal of hepatology · 2026Article
- Unrecognized Fibrosis Risk in MASLD: A Real-World Analysis and the Case for AI-Augmented Stratification.Gastro hep advances · 2026Article
- Global Bivariate Meta-Analysis of FIB-4 Cut-Offs to Rule Out Advanced Fibrosis in MASLD.International journal of hepatology · 2026Article
- The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
- Exposure-shaped immunometabolic networks in chronic liver disease: translating multi-omics and artificial intelligence into preventive biomarkers.Frontiers in immunology · 2026Review
- Transcriptomic, Redox Status and Adipocytokine Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease: Impact of Coexisting Type 2 Diabetes.Medical sciences (Basel, Switzerland) · 2025Article
- Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?Current hepatology reports · 2025Article
- Review
- Accuracy of attenuation coefficient measurement (ACM) for hepatic steatosis: comparison with MRI proton density fat fraction (MRI-PDFF) and chemical fat analysis using multimodal liver fat phantoms.Frontiers in medicine · 2025Article
- Epidemiology and diagnostic of MASLD in Latin America: a yet to be met challenge.Frontiers in pharmacology · 2025Review
- The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what's different?Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic fatty liver disease (MASLD) is a worsening global health issue, affecting over one-third of the adult population and representing the leading cause of liver-related morbidity and mortality. MASLD is not only a key precursor to chronic liver disease, but also a systemic condition that leads to numerous extrahepatic complications, increasing the risk of cardiovascular diseases, chronic kidney disease, type 2 diabetes, and certain cancers. The primary reference method for assessing liver fibrosis, allowing for precise determination of its location and severity, remains liver biopsy. However, it is an invasive procedure and involves certain risks. In recent years, the importance of MASLD diagnosis using noninvasive diagnostic methods has been increasing, including serological markers, methods based on multi-omics, and imaging techniques such as liver elastography. This review presents data on the diagnosis and evaluation of this disease that may find application in future clinical practice. The focus is on presenting both currently used and newly identified noninvasive diagnostic methods that open up the prospect of gradually replacing biopsy in the diagnosis of MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.